DEXCOM INC (DXCM) Form 8-K — Oct 29, 2026
$DXCMForm 8-KItems 2.02, 8.01, 9.01Filed Oct 29, 2026, 4:03 PM ET0001093557-26-000193Original filing
DexCom reported Q3 2026 revenue of $1.344 billion, up 11% year-over-year, with U.S. revenue up 14% and non-GAAP operating income of $339.5 million (25.3% margin). GAAP diluted EPS was $0.72 versus $0.70 a year ago. Management raised full-year 2026 guidance, now expecting revenue of $5.20-$5.25 billion (12-13% growth) with non-GAAP operating margin of approximately 24% and Adjusted EBITDA margin of approximately 32%.
Key figures
- Eps
- $0.72 GAAP diluted / $0.73 non-GAAP diluted
- Revenue
- 1344500000
- Guidance
- FY2026 revenue $5.20-$5.25 billion (~12-13% growth), non-GAAP gross margin ~64%, non-GAAP operating margin ~24%, Adjusted EBITDA margin ~32%
- Net Income
- 275100000
- Cash Position
- 1820000000
- Deal Value Usd
- 0
- Shares Outstanding
- 412700000
- Us revenue growth
- 14% YoY
- Adjusted ebitda q3
- $435.2 million
- Gaap operating income
- $327.2 million (24.3% of revenue, +420 bps YoY)
- Non gaap operating income
- $339.5 million (25.3% of revenue)
- International revenue growth
- 5% YoY
- Share repurchase authorization
- $1.0 billion through December 31, 2027
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.